US FDA clears generic HIV prevention drug from Dr Reddy's

The US Food and Drug Administration has granted tentative approval to Dr Reddy's Laboratories for a generic version of lenacapavir, a twice-yearly injectable drug used for HIV prevention. The clearance paves the way for substantially lower-cost versions of the preventive therapy to reach patients in developing and middle-income markets.

Lenacapavir represents a significant advancement in HIV prevention strategies, offering an alternative to daily oral medications. The twice-yearly injection format is designed to improve adherence and accessibility for populations at higher risk of HIV infection. The generic formulation from Dr Reddy's aims to address affordability barriers that have limited uptake in resource-constrained regions.

The tentative approval encompasses potential distribution across more than 120 countries outside the United States. This regulatory clearance is expected to accelerate the availability of cost-effective HIV prevention options in South Asia, Southeast Asia, and other regions where access to modern preventive therapies remains limited. The move aligns with global efforts to expand antiretroviral-based prevention programmes and reduce new HIV infections.

Dr Reddy's Laboratories, a major pharmaceutical manufacturer based in India, has been instrumental in developing affordable generic versions of HIV medications for emerging markets. The company's approval underscores India's continuing role as a primary supplier of generic antiretroviral drugs to developing countries. Industry observers anticipate this approval will catalyse broader competition in the lenacapavir market, potentially driving further price reductions.